CCR2 and metabolic dysfunction-associated steatohepatitis: C-C chemokine receptor (CCR) antagonists, particularly those targeting CCR2 and CCR5, offer significant therapeutic potential in the treatment of MASH by addressing key mechanisms of hepatic inflammation and fibrosis [304].